Learn More
JASVINDER A. SINGH, DANIEL E. FURST, ASEEM BHARAT, JEFFREY R. CURTIS, ARTHUR F. KAVANAUGH, JOEL M. KREMER, LARRY W. MORELAND, JAMES O’DELL, KEVIN L. WINTHROP, TIMOTHY BEUKELMAN, S. LOUIS BRIDGES JR.,(More)
BACKGROUND Not all patients with rheumatoid arthritis can tolerate or respond to methotrexate, a standard treatment for this disease. There is evidence that antitumour necrosis factor alpha(More)
OBJECTIVE To evaluate the efficacy and safety of adalimumab (D2E7), a fully human monoclonal tumor necrosis factor alpha antibody, in combination with methotrexate (MTX) in patients with active(More)
BACKGROUND Neutralization of tumor necrosis factor a (TNF-alpha) for three to six months reduces the symptoms and signs of rheumatoid arthritis. However, the capacity of this approach to effect a(More)